Cryoport (CYRX) Q3 2026 earnings review
Cryoport's cell therapy services grow fast, while freezer margins narrow
Cryoport, which ships and stores temperature-sensitive living medicines and makes cryogenic freezers, grew faster across both divisions and cleared a clean profitability hurdle. Third-quarter sales rose 14% from a year ago to $50 million, as 20% growth in commercial cell-therapy services combined with an 8% rebound in freezer sales. Chief executive Jerrell Shelton raised the full-year revenue plan above what the prior outlook implied for the second half, while by our math leaving fourth-quarter sales flat with the third quarter.
| Revenue | $50.2M +14% from a year ago |
|---|---|
| Life Sciences Services revenue | $28.6M +18% from a year ago |
| Operating profit (adjusted Ebitda) | $1.1M -$0.6M a year ago, with zero one-off add-backs |
| Full-year 2026 revenue outlook | Raised $4M middle of the range: $198M (+12% growth) |
⚖️ Verdict: 🟢 Bullish
The story got better because Cryoport generated $1.1 million of operating profit before interest, taxes, depreciation and one-offs without the unexplained accounting adjustment that propped up last quarter's result. Late-stage clinical trials also reached 99, confirming steady pipeline progress. Two cautions remain: gross margin in the freezer division fell 2.8 percentage points despite higher sales, and drugmakers pushed four regulatory filings from 2026 into 2027.
The question now is whether Cryoport can keep expanding operating profit as new service hubs come online in Paris and California, or whether start-up costs and weaker freezer margins will stall the recovery. If higher shipping and storage volumes cover the new facility costs, operating profit will rise again; if hardware margins stay depressed, progress will flatten. Fourth-quarter segment margins will tell.
🐂 Bull Case
Operating Profit Excluding One-offs Is Now Genuine
Cryoport measures its operating progress using adjusted EBITDA, which is profit before interest, taxes, depreciation, stock pay, and one-off items. Last quarter, the life-sciences shipper barely cleared break-even on this measure at $0.4 million, and only because it added back $1.1 million of unexplained one-off expenses. Without that adjustment, the business lost $0.8 million by our math.
In the third quarter, adjusted EBITDA rose to $1.1 million, which chief executive Jerrell Shelton called "representing another important milestone in our pathway to profitability initiative". This time, the reconciliation table shows zero in that miscellaneous adjustment line. Selling and administrative overhead — the cost of the sales force and corporate staff — dropped by 4.9 percentage points of revenue from a year ago, while engineering costs fell 0.8 percentage points.
What to watch: adjusted EBITDA in the fourth quarter as Cryoport adds storage services at its new hubs in Paris and Santa Ana, California. A third straight positive figure without new one-off adjustments would prove the network can absorb expansion costs while growing profit.
Cell Therapy Shipping and Storage Accelerate
Cryoport's main growth engine is Life Sciences Services, which ships and stores living human cells at deep-freeze temperatures for drug developers. Services revenue grew 18% from a year ago to $28.6 million, making up 57% of total company sales. That beat the 15% pace from the second quarter even though the third quarter faced a tougher comparison from a year ago.
- Commercial cell and gene therapy revenue: up 20% from a year ago to about $10.0 million, across 23 approved drugs
- BioStorage and BioServices (storing, packaging and labelling therapies): up 25% to $6.0 million
- BioLogistics Solutions (temperature-controlled shipping): up 16% to $22.5 million
- Supported clinical trials: a record 788, with late-stage Phase 3 trials up 19% from a year ago to 99
This matters because customers are buying storage and sterile packaging alongside transport, which finance chief Robert Stefanovich said increases Cryoport's share of customer spending. Better biotech funding and acquisitions by large drugmakers like Gilead are also pushing more trials into late-stage testing, chief scientific officer Mark Sawicki said.
What to watch: commercial cell and gene therapy revenue growth in the fourth quarter and full-year 2027. Keeping growth near 20% as new approvals convert into patient shipments would confirm steady compounding.
🐻 Bear Case
Freezer Sales Grew While Margins Dropped
Cryoport also makes cryogenic freezers and shipping containers under the MVE Biological Solutions brand, which brings in 43% of company revenue. After stagnating in the second quarter, product sales rose 8.4% from a year ago to $21.7 million. Stefanovich said "MVE is robust. it is stable. Its market seems to have stabilized." Shelton credited cattle reproduction customers and the new self-sustaining Fusion freezers.
The sales rebound fixed the revenue stall, but profitability inside the freezer unit went the other way. Product gross margin — the share of freezer sales left after manufacturing costs — fell by 2.8 percentage points from a year ago to 43.6%. The cost of making the products rose from 53.6% of segment sales to 56.4%, which pulled Cryoport's total gross margin down by 0.7 percentage points to 47.5%.
This cuts against management's claim that the hardware business is back on track, because Products gross margin has now fallen from a year ago for three straight quarters. Shelton also noted that demand from cattle breeders is cyclical, and shipping containers grew faster than higher-priced laboratory freezers.
What to watch: Products gross margin in the fourth quarter against last year's 46.8%. A fourth straight drop would show that lower-margin shipping containers and livestock customers are permanently diluting the hardware business toward a 42–43% gross margin.
Customer Drug Filings Slipped Into Next Year
Cryoport's future commercial revenue depends on drug developers filing Biologics License Applications (BLA) or European marketing applications (MAA) and winning regulatory approval. Three months ago, the company anticipated up to 11 customer filings and five new drug approvals during the second half of 2026.
This quarter, customers filed only two applications and won one new approval, for Replimune's skin cancer therapy TUDRIQEV. For the fourth quarter, Cryoport now anticipates five possible filings and two approvals, which have FDA decision dates in November and December. "4 applications that we thought we would have happen in 2026 did get pushed into 2027," Sawicki said.
Stefanovich noted that new approvals do not hurt the 2026 outlook because commercial launches take months to ramp up. However, because approvals take six to twelve months to generate meaningful shipping volume, four delayed filings push those commercial revenue streams from late 2027 into 2028.
What to watch: the FDA decisions on the Arcellx and Capricor therapies in November and December, plus the 2027 filing calendar on the next call. Delays on those two decisions would slow the commercial therapy count entering 2027.
Risks This Quarter Didn't Answer
Four standing balance-sheet, operational and concentration concerns received little or no new financial detail in the third-quarter release and call.
- Convertible debt maturity: $186.0 million of senior notes come due in December 2026, which will consume nearly half of Cryoport's $393.1 million cash pile; the year-end balance sheet will show the post-repayment cash cushion.
- New hub start-up costs: Santa Ana opened for shipping in Q3, but adding storage services in Paris and Santa Ana runs into 2027, and management did not quantify the early margin drag.
- IntegriCell revenue: the cell-freezing service has onboarded clients in Houston and Belgium and will add New Jersey in 2027, but management still gives no revenue figure.
- Preferred stock dilution and customer concentration: Blackstone's preferred shares took another $2.0 million in quarterly stock dividends, and the quarterly filing will show whether one client still exceeds 10% of sales.
👓 Other Themes
Cautious Q4 Outlook Points to Flat Sales
Cryoport raised its full-year revenue outlook to $197–199 million, which by our math leaves $50.0–52.0 million for the fourth quarter, barely above the third quarter's $50.2 million. Asked why fourth-quarter sales would stall, Shelton said: "Look. there is still a lot of external things, especially with our government and so forth, that could happen, and we just have to take those take those into consideration." Meanwhile, China sales stabilized at 3–4% of revenue.
💲 Other KPIs
Total cash and short-term investments edged down by $3.6 million from last quarter's $396.7 million, and is down $18.1 million since the start of the year. The slow cash burn reflects positive operating cash flow offset by capital spending on the Santa Ana and Paris supply chain centers ahead of December's $186.0 million debt maturity.
Money owed by customers fell slightly from $36.5 million in the second quarter and rose just 3.1% from a year ago, well below the 13.5% rise in third-quarter revenue. Collecting cash faster than sales grow shows healthy customer payments across biotech and pharmaceutical accounts.
The bottom-line loss widened from $8.9 million (-$0.18 per share) a year ago and $10.3 million (-$0.20 per share) last quarter, even though operating loss shrank by $1.1 million. A $4.2 million paper loss on short-term investments and the $2.0 million preferred stock dividend caused the wider net loss.
🔮 Guidance
Raised. Cryoport lifted the middle of its full-year plan by $4.0 million, calling for 12.4% growth for the year. By our math, that leaves $51.0 million for the fourth quarter at the middle of the range, up 12.2% from a year ago and 1.6% from the third quarter. It is the second raise this year (+$2M in Q1, held in Q2, +$4M in Q3); if last year's fourth-quarter beat pattern holds, full-year sales would reach $202.8 million by our math.
❓ Key Questions
Why did freezer gross margin drop 2.8 points as sales grew?
Products revenue rose 8.4% from a year ago, yet segment gross margin fell to 43.6% from 46.4% a year ago. Management did not explain how much came from cattle-breeder shipping containers versus factory costs or tariffs.
How will Cryoport deploy its remaining $207 million cash after December?
Paying off the $186.0 million convertible notes in December 2026 leaves roughly $207 million in cash and investments. The company has not bought back shares in 2026 despite having $63.9 million authorized.
What revenue is IntegriCell generating across Houston and Belgium?
Cryoport plans to open a third cell-freezing site in New Jersey next year to support customer demand, but has not disclosed how many patients or dollars the first two sites have brought in.
Why did four customer regulatory applications slip into 2027?
Drug developers pushed four expected 2026 filings into 2027. Knowing whether FDA feedback, manufacturing readiness, or clinical data caused the delays would clarify when those therapies might reach commercial launch.